Biopharma company UCB will reformulate its Parkinson's disease and restless leg syndrome drug Neupro before making it available on the U.S. market, per recommendation of the FDA. The regulator's decision answers an NDA supplement submitted by the Belgian drugmaker in June 2009, which proposed new refrigerated storage conditions to alleviate crystallization on the transdermal patches. The FDA agreed that improved storage helped alleviate the problem, but reformulation provided "definitive resolution." Item